The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers

Journal of Nuclear Medicine

Volumn 49, Issue 10, 2008, Pages 1664-1667

  McParland, Brian J ^a,b   Miller, Matthew P ^a   Spinks, Terence J ^c   Kenny, Laura M ^c   Osman, Safiye ^c   Khela, Mandeep K ^a   Aboagye, Eric ^c   Coombes, Raoul C ^c   Hui, Ai Min ^a   Cohen, Pamela S ^a  

^a GE Healthcare   (United States)

^b GE HEALTHCARE   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

v 3 expression; 18F AH111585; Dosimetry; PET; Whole body biodistribution

Indexed keywords

AH 111585 F 18; ARGINYLGLYCYLASPARTIC ACID; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLADDER WALL; DOSIMETRY; DRUG DISTRIBUTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; URINARY EXCRETION;

AGED; ARGININE; ASPARTIC ACID; AZETIDINES; FEMALE; GLYCINE; HUMANS; MALE; MIDDLE AGED; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RADIATION DOSAGE; RADIOMETRY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 53749107069     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.052126     Document Type: Article

References (18)

1. Cox D, Aoki T, Seki J, Motoyama Y, Yoshida K. The pharmacology of integrins. Med Res Rev. 1994;14:192-228.
2. Brooks PC. Role of integrins in angiogenesis. Eur J Cancer. 1996;32:2423-2429.
3. Dredge K, Dalgeish AG, Marriott JB. Recent developments in antiangiogenic therapies. Expert Opin Biol Ther. 2002;2:953-966.
4. 18F-galacto-RGD in cancer patients. J Nucl Med. 2005;46:1333-1341.
5. 99mTc- NC100692. J Nucl Med. 2006;47:1434-1439.
6. 18F-AH111585 in breast cancer patients. J Nucl Med. 2008;49:879-886.
7. Loevinger R, Budinger T, Watson E. MIRD Primer for Absorbed Dose Calculations. New York, NY: Society of Nuclear Medicine; 1988.
8. Indrevoll B, Kindberg GM, Solbakken M, et al. NC-100717: a versatile RGD peptide scaffold for angiogenesis imaging. Bioorg Med Chem Lett. 2006;16:6190-6193.
9. Hudson HM, Larkin R. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging. 1994;13:601-609.
10. Defrise M, Kinahan PE, Michel CJ. Image reconstruction algorithms in PET. In: Bailey DL, Townsend DW, Valk PE, et al., eds. Positron Emission Tomography: Basic Sciences. London, U.K.: Springer-Verlag; 2003:91-114.
11. ICRP Publication 89: Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values, 89. Oxford, England: Elsevier; 2003.
12. International Commission on Radiological Protection. Limits for Intakes of Radionuclides by Workers. ICRP Publication 30, Part 1. Annals of the ICRP, 2(3/4). Oxford, England: Pergamon Press; 1979.
13. Cloutier RJ, Smith SA, Watson EE, Snyder WS, Warner GG. Dose to the fetus from radionuclides in the bladder. Health Phys. 1973;25:147-161.
14. International Commission on Radiological Protection. Age-Dependent Doses to Members of the General Public from Intake of Radionuclides. Publication 56, Part 2. Oxford, England: Pergamon Press; 1992.
15. Stabin MG, Sparks RB, Crewe E. OLINDA/EXM: the second generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
16. International Commission on Radiological Protection. Recommendations of the International Commission on Radiological Protection. Publication 60. Oxford, England: Pergamon Press; 1991.
17. International Commission on Radiological Protection. Annual Limits of Intake by Radionuclides by Workers Based on the 1990 Recommendations. Publication 61. Oxford, England: Pergamon Press; 1991.
18. International Commission on Radiological Protection. Radiation Dose to Patients from Radiopharmaceuticals, Addendum 2 to ICRP Publication 53. Publication 80. Oxford, England: Pergamon Press; 1998